Hao Yan

EPS Holdings, Inc. engages in the drug development business. It operates through the following segments: Contract Research Organization (CRO), Site Management Organization (SMO), Contract Sales Organization (CSO), Global Research, Ekishin, and Others. The CRO segment offers clinical trials, data management, and statistical analysis. The SMO segment enters into contracts with medical institutions to conduct clinical trials. The CSO segment provides drug information and awareness for medical and pharmaceutical industries. The Global Research segment provides consignment services through its subsidiary for multilateral clinical trials in Asia-Pacific. The Ekishin segment focuses on medical equipment, pharmaceutical and investment related businesses through its Japan and China based subsidiaries. The Others segment provides various services related to management of clinical research from business processing outsource business related to medicine and medical care. The company was founded on May 30, 1991 and is headquartered in Tokyo, Japan.

Y&G Ltd. operates as an investment firm. The company is based in Tokyo, Japan.

EPS International Co. Ltd. a subsidiary of a public listed company EPS Co. Ltd in Tokyo, Japan, commences its business operations in April 2007. The company aims to provide a seamless clinical research and development platform through strategizing and synergizing its established research networks, valuable knowledge, know-how, resources and experiences in Asia region. The company manages large- and small-scale, global and local clinical trials covering from first-in-man to post marketing surveillance for new chemical entities, biologics and medical devices.

EPS China Co., Ltd. engages in the research, development, manufacture, and sales of medical devices, pharmaceuticals, and research equipment. It operates through the following businesses: Pharmaceutical, Medical Instrument, Contract Research Organization Plus (CRO+) Professional Services, International Trade, Investment, and EPS Plus Supporting. The Pharmaceutical business builds a complete industrial chain of pharmaceutical products from research and development to sales. The Medical Instrument business sells medical equipment and consumables, and provides after-sales services. The CRO+ Professional Services business provides clinical trial services and builds medical service platform. The International Trade business offers equipment and materials for pharmacological research and other preclinical trials, as well as provides professional services for new drug development. The Investment business provides financial support for companies and research projects through direct investment and funds. The EPS Plus Supporting business offers research and development, incubation, production base and other carrier construction and lease management, education and training, and exchange of scientific and educational resources in the academic world. EPS China was founded by December 26, 2008 and is headquartered in Suzhou, China.

The Chinese Chamber of Commerce in Japan (CCCI) is an organization that provides business activity trends and news related to China. The location of the private company is in Tokyo, Japan. The Japanese company also offers enrollment services, access to a library, and links to various resources.

Part of EPS Holdings, Inc., EPS Global Research, Inc. operates clinical trials.

EP-PharmaLine Co., Ltd. provides recruitment, training, and support services to the medical and healthcare industries. It offers contract sales organization, drug information services, business process outsourcing, and medical equipment support services. The firm also provides support services including medical call center, healthcare, post marketing surveillance, pharmaceutical distribution management, emergency key management center, and convention support services. The company was founded in October 2013 and is headquartered in Tokyo, Japan.